- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06222879
Study of HRS-8080 or SHR-A2009 Combined With Anti-tumor Therapy in Patients With Unresectable or Metastatic Breast Cancer
January 15, 2024 updated by: Shandong Suncadia Medicine Co., Ltd.
A Multi-center, Open-label Phase Ib/II Clinical Study on the Safety, Tolerability, Pharmacokinetics and Efficacy of HRS-8080 or SHR-A2009 Combined With Anti-tumor Therapy in Patients With Unresectable or Metastatic Breast Cancer
This study is designed to determine if treatments with the combination of HRS-8080 and SHR-A1811, the combination of HRS-8080 and SHR-A2009, the combination of SHR-A2009 and SHR-1316 are safe, tolerable, and has anti-cancer activity in patients with unresectable or metastatic breast cancer.
Study Overview
Status
Not yet recruiting
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Estimated)
350
Phase
- Phase 2
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Na An
- Phone Number: +86 18500038119
- Email: na.an@hengrui.com
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Females aged 18-75 years old (both ends inclusive);
- ECOG performance status (PS) 0-1 points;
- Patients with metastatic or locally advanced breast cancer confirmed by histology(ER positive, HER2 positive/negative,or triple negative breast cancer).
- Tumor tissue samples must be provided for detection of tumor markers;
- Menopausal state;
- Disease progression confirmed by imaging during or after the last systemic treatment before enrollment;
- There must be at least one measurable extracranial lesion that complies with RECIST v1.1;
- Expected survival >3 months;
- Good functional level of the organs ;
- Female subjects with childbearing potential must agree to use highly effective contraceptive measures during the study treatment period and within 7 months after the end of the study treatment period; female subjects with childbearing potential must agree to use serum serum within 7 days before study enrollment. The HCG test must be negative and the patient must be non-lactating;
- Voluntarily participate in this clinical trial, be willing and able to comply with clinical visits and research-related procedures, understand the research procedures and have signed informed consent.
Exclusion Criteria:
- Patients with active (without medical control or clinical symptoms) brain metastasis;
- Have the following lung diseases or history;
- History of clinically severe cardiovascular disease;
- Those who have received immunosuppressants or systemic hormone therapy for immunosuppression within 2 weeks before the first dose (dose >10 mg/d prednisone or other corticosteroids at equivalent physiological doses), excluding nasal spray or inhaled hormones;
- The damage caused by the subject receiving other treatments has not recovered (severity level NCI-CTCAE V5.0 classification ≤1, excluding hair loss and other adverse events judged to be tolerable by the researcher);
- There are serious infections within 4 weeks before the first medication;
- Untreated active hepatitis;
- The subject has suffered from other malignant tumors in the past 5 years or currently, excluding cured cervical carcinoma in situ, cutaneous basal cell carcinoma and squamous cell carcinoma;
- Presence of active autoimmune disease;
- Have a history of immunodeficiency, including acquired (HIV infection), congenital immunodeficiency diseases, or a history of organ transplantation (including allogeneic bone marrow transplantation);
- The subject is in the acute infection stage or active tuberculosis and requires drug treatment;
- Known to be allergic to the components of HRS-8080, SHR-A1811 and its components, SHR-A2009 and its components, and Adebrelimab; have a history of severe allergic reactions to other monoclonal antibodies;
- Patients who have other serious physical or mental illnesses or laboratory test abnormalities that may increase the risk of participating in the study or interfere with the results of the study, and who the researcher believes are not suitable for participation in this study.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Part A
|
Participants will receive HRS-8080 and SHR-A1811
|
Experimental: Part B
|
Participants will receive HRS-8080 and SHR-A2009
|
Experimental: Part C
|
Participants will receive SHR-A2009 and SHR-1316
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Dose Limited Toxicity(DLT)
Time Frame: up to 1 cycle (21 days)
|
Phase 1
|
up to 1 cycle (21 days)
|
Maximum Tolerable Dose(MTD)
Time Frame: up to 1 cycle (21 days)
|
Phase 1
|
up to 1 cycle (21 days)
|
Recommended Phase 2 Dose(RP2D)
Time Frame: up to 1 cycle (21 days)
|
Phase 1
|
up to 1 cycle (21 days)
|
Safety endpoints: the incidence and severity of adverse events (AEs) and serious adverse events (SAEs) (rated based on CTCAE V5.0)
Time Frame: up to 12 months
|
Phase 1
|
up to 12 months
|
Efficacy endpoint: objective response rate (ORR)
Time Frame: up to 12 months
|
Phase 2
|
up to 12 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
level of SHR-A1811 ADA and Nab
Time Frame: up to 12 months
|
Phase 1
|
up to 12 months
|
level of SHR-A2009 ADA and Nab
Time Frame: up to 12 months
|
Phase 1
|
up to 12 months
|
level of adebrelimab ADA and Nab
Time Frame: up to 12 months
|
Phase 1
|
up to 12 months
|
Objective response rate (ORR)
Time Frame: up to 12 months
|
Phase 1
|
up to 12 months
|
Best overall response (BOR)
Time Frame: up to 12 months
|
Phase 1
|
up to 12 months
|
Duration of response (DoR)
Time Frame: up to 12 months
|
Phase 1
|
up to 12 months
|
Disease control rate (DCR)
Time Frame: up to 12 months
|
Phase 1
|
up to 12 months
|
Clinical benefit rate (CBR)
Time Frame: up to 12 months
|
Phase 1
|
up to 12 months
|
Progression-free survival (PFS)
Time Frame: up to 12 months
|
Phase 1
|
up to 12 months
|
Safety endpoints: incidence and severity of AEs and SAEs (rated based on CTCAE V5.0)
Time Frame: up to 12 months
|
Phase 2
|
up to 12 months
|
level of SHR-A1811 ADA and Nab
Time Frame: up to 12 months
|
Phase 2
|
up to 12 months
|
level of SHR-A2009 ADA and Nab
Time Frame: up to 12 months
|
Phase 2
|
up to 12 months
|
level of adebrelimab ADA and Nab
Time Frame: up to 12 months
|
Phase 2
|
up to 12 months
|
Best overall response (BOR)
Time Frame: up to 12 months
|
Phase 2
|
up to 12 months
|
Duration of response (DoR)
Time Frame: up to 12 months
|
Phase 2
|
up to 12 months
|
Disease control rate (DCR)
Time Frame: up to 12 months
|
Phase 2
|
up to 12 months
|
Clinical benefit rate (CBR)
Time Frame: up to 12 months
|
Phase 2
|
up to 12 months
|
Progression-free survival (PFS)
Time Frame: up to 12 months
|
Phase 2
|
up to 12 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Estimated)
January 1, 2024
Primary Completion (Estimated)
October 31, 2026
Study Completion (Estimated)
October 31, 2026
Study Registration Dates
First Submitted
December 4, 2023
First Submitted That Met QC Criteria
January 15, 2024
First Posted (Estimated)
January 25, 2024
Study Record Updates
Last Update Posted (Estimated)
January 25, 2024
Last Update Submitted That Met QC Criteria
January 15, 2024
Last Verified
January 1, 2024
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- HRS-8080-202
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
UNDECIDED
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Breast Cancer
-
Northwestern UniversityEisai Inc.UnknownMale Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative...United States
-
Rutgers, The State University of New JerseyNational Cancer Institute (NCI); Rutgers Cancer Institute of New JerseyActive, not recruitingStage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative Breast CancerUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI)TerminatedMale Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
-
University of WashingtonTerminatedBreast Cancer | Breast Cancer Stage I | Breast Cancer Stage II | Breast Cancer Stage III | Breast Cancer Stage IIB | Breast Cancer Stage IIA | Breast Cancer Stage IIIA | Breast Cancer Stage IIIB | Breast Cancer Stage IIIcUnited States
-
CelgeneCompletedBreast Cancer | Metastatic Breast Cancer | Stage IV Breast Cancer | Triple-negative Breast Cancer | Recurrent Breast Cancer | Breast Tumor | Cancer of the Breast | Triple-negative Metastatic Breast Cancer | Estrogen Receptor- Negative Breast Cancer | HER2- Negative Breast Cancer | Progesterone Receptor- Negative...United States, United Kingdom, Italy, Germany, Spain, Canada, Portugal, Australia, Austria, Greece, Brazil, France
-
University of Southern CaliforniaNational Cancer Institute (NCI)TerminatedHER2-positive Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
-
University of WashingtonNational Cancer Institute (NCI)CompletedHER2-positive Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Estrogen Receptor-negative Breast Cancer | Estrogen Receptor-positive Breast Cancer | Progesterone Receptor-negative Breast Cancer | Progesterone Receptor-positive Breast...United States
-
University of WashingtonNational Cancer Institute (NCI)CompletedHER2-positive Breast Cancer | Male Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
-
Sidney Kimmel Cancer Center at Thomas Jefferson...Susan G. Komen Breast Cancer FoundationCompletedStage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative Breast CancerUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI)WithdrawnStage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast Cancer
Clinical Trials on HRS-8080; SHR-A1811
-
Henan Cancer HospitalRecruitingHER2 Low Breast CarcinomaChina
-
Jiangsu HengRui Medicine Co., Ltd.RecruitingAdvanced Non-small Cell Lung CancerChina
-
Shengjing HospitalJiangsu HengRui Medicine Co., Ltd.Not yet recruitingER Positive/HER2 Low Breast CancerChina
-
Shandong Suncadia Medicine Co., Ltd.RecruitingUnresectable or Metastatic Breast CancerChina
-
Jiangsu HengRui Medicine Co., Ltd.Recruiting
-
Jiangsu HengRui Medicine Co., Ltd.RecruitingAdvanced Non-small Cell Lung CancerChina
-
Jiangsu HengRui Medicine Co., Ltd.Atridia Pty Ltd.RecruitingAdvanced Solid TumorsChina, Korea, Republic of, Taiwan, United States, Australia
-
Jiangsu HengRui Medicine Co., Ltd.Active, not recruitingGastric Cancer | Colorectal CancerChina
-
Fudan UniversityRecruiting
-
Jiangsu HengRui Medicine Co., Ltd.RecruitingHER2-expressing Advanced Solid TumorsChina